After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

Former Vice President Atiku Abubakar, 2023 Labour Party presidential candidate Peter Obi, former Senate President David Mark and other coalition leaders have officially adopted the African Democratic ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

NEW YORK--(BUSINESS WIRE)--Flowcode, the enterprise QR code platform delivering unique custom experiences, announced a partnership today with fast growing, emerging snack brand LOVE CORN, marking the ...

NEW YORK--(BUSINESS WIRE)--Flowcode, a marketing technology platform, has partnered with embedded insurance technology company REIN to streamline insurance purchases by making it easier to secure a ...

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study. Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve ...